SSS Sunvest Minerals Corp

Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) today announced its
financial results for the period ended March 31, 2008.


Selected Highlights

During the first quarter of 2008 and up to May 20, 2008, SCT achieved the
following accomplishments:


- Released formal results from the Phase IIa 'BETAS' acute stroke study in
February 2008 that demonstrated favourable safety and efficacy outcomes from the
Phase IIa stroke trial.


- On April 23, 2008, SCT received a "May Proceed" from the Food and Drug
Association (FDA) for the US Phase IIb clinical stroke trial to allow the
investigational new drug (IND) application to proceed. This US Phase IIb acute
ischemic stroke study accompanies the currently enrolling Phase IIb Canadian
'REGENESIS' study for acute ischemic stroke.


- Began recruiting patients for the Phase IIb 'REGENESIS' study on May 2, 2008.

Upcoming 2008 Milestones

- Complete enrolment in the Phase IIb clinical stroke study for NTx(TM)-265

- Initiate Phase IIa clinical study for Traumatic Brain Injury

- Complete animal efficacy studies for Multiple Sclerosis

Capital Position

As of March 31, 2008 the working capital (current assets minus current
liabilities) of the Company was $7,912,901 ($9,138,263 as of March 31, 2007).


Outstanding securities as of March 31, 2008 and May 20, 2008 totaled 103,529,864
common shares, 6,000,000 class B shares, 25,912,500 common share purchase
warrants and 7,680,556 common share options.


Financial Review

The Company's loss for the three month period ended March 31, 2008 increased by
$103,457 to $1,354,186 ($0.01 per common share) from the loss of $1,250,729
($0.02 per common share) reported for the three month period ended March 31,
2007. The primary reason for the increase in loss was an increase in research
and development costs offset by a decrease in management and consulting fees,
stock-based compensation and an increase in interest income. The March 31, 2008
"Management Discussion and Analysis" provides further details on these operating
results.


About NTx(TM)-265: NTx(TM)-265 is a therapeutic regimen of two approved and
clinically well-defined drugs, human Chorionic Gonadotropin (hCG) and
Erythropoietin (EPO), targeting the treatment of stroke. The twin objectives of
the regimen are to stimulate the growth and differentiation of new neurons to
replace the brain cells that were lost or damaged by the stroke, and
importantly, to direct motor, visual and cognitive recovery after acute ischemic
stroke. Animal studies have shown a significant recovery in motor function after
receiving the NTx(TM)-265 regimen 24-48 hours post stroke. Encouraging clinical
results in SCT's Phase IIa 'BETAS' stroke trial were presented at the
International Stroke Conference in February 2008, showing clinically relevant
recovery in 8 of 8 patients who received the complete regimen. SCT is recruiting
patients for the multi-centre, double-blind, placebo-controlled Phase IIb
'REGENESIS' study for NTx(TM)-265 with primary endpoints of efficacy. Patient
enrolment is expected to be complete by the end of 2008 with top-line efficacy
data expected to be released in the first quarter of 2009.


About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a Canadian
public biotechnology company (TSX-V: SSS) focused on the development and
commercialization of drug-based therapies to treat central nervous system
diseases. SCT is a leader in the development of therapies that utilize drugs to
stimulate a patient's own resident stem cells. The company's programs aim to
repair neurological function lost due to disease or injury. The company's
extensive patent portfolio of owned and licensed intellectual property supports
the potential expansion into future clinical programs in numerous neurological
diseases such as traumatic brain injury and multiple sclerosis.


These securities have not been registered under the United States Securities Act
of 1933, as amended, or the securities laws of any state, and may not be offered
or sold within the United States or to, or for the account or benefit of U.S.
persons unless an applicable exemption from U.S. registration requirements is
available.


Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024